Multiple substrate binding by cytochrome P450 3A4: Estimation of the number of bound substrate molecules

Drug Metabolism and Disposition

Volumn 36, Issue 10, 2008, Pages 2136-2144

  Kapelyukh, Yury ^a   Paine, Mark J I ^a,d   Maréchal, Jean Didier ^c,e   Sutcliffe, Michael J ^c,f   Wolf, C Roland ^a,b   Roberts, Gordon C K ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b CXR Biosciences Ltd   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 BENZYLOXYQUINOLINE; BROMOCRIPTINE; CYCLOSPORIN A; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; KETOCONAZOLE; MIDAZOLAM; TESTOSTERONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DEBENZYLATION; DRUG METABOLISM; ENZYME SUBSTRATE COMPLEX; MICHAELIS MENTEN KINETICS; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; STEADY STATE; STOICHIOMETRY;

CATALYTIC DOMAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DILTIAZEM; HUMANS; KINETICS; MIDAZOLAM; MODELS, MOLECULAR; SPECTROPHOTOMETRY, ULTRAVIOLET; SUBSTRATE SPECIFICITY;

EID: 52949113775     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021733     Document Type: Article

References (43)

1. Atkins WM (2005) Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu Rev Pharmacol Toxicol 45:291-310.
2. Atkins WM, Lu WYD, and Cook DL (2002) Is there a toxicological advantage for non-hyperbolic kinetics in cytochrome P450 catalysis? Functional allostery from "distributive catalysis." J Biol Chem 277:33258- 33266.
3. Atkins WM, Wang RW, and Lu AYH (2001) Allosteric behavior in cytochrome P450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. Chem Res Toxicol 14:338-347.
4. Baas BJ, Denisov IG, and Sliger SG (2004) Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. Arch Biochem Biophys 430:218-228.
5. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, and Bourne PE (2000) The Protein Data Bank. Nucl Acids Res 28:235-242.
6. Burton RL, Chen S, Xu XL, and Grant GA (2007) A novel mechanism for substrate inhibition in Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase. J Biol Chem 282: 31517-31524.
7. Cameron MD, Wen B, Allen KE, Roberts AG, Schuman JT, Campbell AP, Kunze KL, and Nelson SD (2005) Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: A NMR T-1 paramagnetic relaxation study. Biochemistry 44:14143-14151.
8. Cleland WW (1979) Substrate inhibition. Methods Enzymol 63:500-513.
9. Dabrowski MJ, Schrag ML, Wienkers LC, and Atkins WM (2002) Pyrene-pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J Am Chem Soc 124:11866-11867.
10. Denisov IG, Baas BJ, Grinkova YV, and Sligar SG (2007) Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation. J Biol Chem 282:7066-7076.
11. Ekroos M, and Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103:13682-13687.
12. Fernando H, Halpert JR, and Davydov DR (2006) Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry 45:4199-4209.
13. Fisher HF, Gates RE, and Cross DG (1970) A ligand exclusion theory of allosteric effects. Nature 228:247-249.
14. Fowler SM, Taylor JM, Friedberg T, Wolf CR, and Riley RJ (2002) CYP3A4 active site volume modification by mutagenesis of leucine 211. Drug Metab Dispos 30:452-456.
15. Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31:1108-1116.
16. Guengerich FP (2005) Human cytochrome P450 enzymes, in: Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano PR ed), pp 377-530, Kluwer Academic/Plenum, New York.
17. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4: role of residues 210 and 211 in flavonoid activation and substrate specificity. J Biol Chem 272:5396-5402.
18. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci U S A 95:6636-6641.
19. Hosea NA, Miller GP, and Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
20. Houston JB and Galetin A (2003) Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 35:393-415.
21. Houston JB and Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351-360.
22. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
23. Isin EM and Guengerich FP (2006) Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 281:9127-9136.
24. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, and Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116- 1125.
25. Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495-506.
26. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
27. Lampe JN and Atkins WM (2006) Time-resolved fluorescence studies of heterotropic ligand binding to cytochrome P450 3A4. Biochemistry 45:12204-12215.
28. LiCata VJ and Allewell NM (1997) Is substrate inhibition a consequence of allostery in aspartate transcarbamylase? Biophys Chem 64:225-2347.
29. Maréchal JD, Yu J, Brown S, Kapelioukh I, Rankin EM, Wolf CR, Roberts GCK, Paine MJI, and Sutcliffe MJ (2006) In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by co-medications commonly used by patients with cancer. Drug Metab Dispos 34 534-538.
30. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
31. Pastra-Landis SC, Evans DR, and Lipscomb WN (1978) The effect of pH on the cooperative behavior of aspartate transcarbamylase from Escherichia coli. J Biol Chem 253:4624-46308.
32. Roberts AG, Campbell AP, and Atkins WM (2005) The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria. Biochemistry 44:1353-1366.
33. Segel IH (1975) Enzyme Kinetics, Wiley, New York.
34. Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, et al. (2001) Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2:17-36.
35. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
36. Stresser DM, Turner SD, Blanchard AP, Miller VP, and Crespi CL (2002) Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos 30:845-852.
37. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
38. Ueng YF, Kuwabara T, Chun YJ, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
39. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, and Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609-623.
40. Wang RW, Newton DJ, Scheri TD, and Lu AYH (1997) Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation: competition during catalysis. Drug Metab Dispos 25:502-507.
41. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686.
42. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-angstrom resolution. J Biol Chem 279:38091-38094.
43. Zhang Z, Li Y, Shou M, Zhang Y, Ngui JS, Stearns RA, Evans DC, Baillie TA, and Tang W (2004) Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4. Xenobiotica 34:473-486.